Eligibility, Clinical Outcomes, and Budget Impact of PCSK9 Inhibitor Adoption: The CANHEART PCSK9 Study

BACKGROUND: The FOURIER (Further Cardiovascular Outcomes Research With PCSK9i [Proprotein Convertase Subtilisin‐Kexin Type 9 Inhibitors] in Subjects With Elevated Risk) trial found a reduction in cardiovascular events in patients with atherosclerotic cardiovascular disease (ASCVD). Our objective was...

Descripción completa

Detalles Bibliográficos
Autores principales: Ko, Dennis T., Khan, Anam M., Kotrri, Gynter, Austin, Peter C., Wijeysundera, Harindra C., Koh, Maria, Chu, Anna, Jackevicius, Cynthia A., Lawler, Patrick R., Tu, Jack V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6404170/
https://www.ncbi.nlm.nih.gov/pubmed/30571382
http://dx.doi.org/10.1161/JAHA.118.010007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6404170/
https://www.ncbi.nlm.nih.gov/pubmed/30571382
http://dx.doi.org/10.1161/JAHA.118.010007

Ejemplares similares